From Phase I to Market Access: A Lifecycle Approach to Life Sciences Risk Management

Introduction to the Modern Life Sciences Industry

Medicine has always been a vital part of human life. As technology has evolved, humans have built better medical solutions to eradicate disease, improve life expectancy, and treat chronic illnesses. But innovation isn’t without risk. Compliance is key to mitigating this risk, safeguarding health, and reining in advancements too premature for commercialization.

As the life sciences industry has advanced, safety practices have evolved to navigate complex regulatory landscapes. This includes risk assessments and vital risk exposure management so companies can stay afloat when difficulties arise. This includes litigation, patient safety, financial risks, operational risks, and more.

Today, innovators face regulatory bodies like the Food and Drug Administration (FDA) in the US, the European Medicines Agency (EMA), and the National Health Surveillance Agency (ANVISA) in Brazil, among others. These regulatory boards keep patient health a top priority amid a flurry of biotech advancements.

Modern risks require modern risk management solutions, and the most competitive life science organizations respond with a blend of management strategies, compliance systems, and insurance coverage types tailored to their unique levels of risk.

The Proof of Concept Era: Risk Assessments for Phase I & II

Building a strong product from the start sets the foundation for a successful life sciences startup in the future. Equally, life science companies that proactively factor risk management into protecting proprietary research, establishing vendor partnerships, and structuring clinical trial oversight set themselves up for long-term success.

Mitigating Risks with the Intellectual Seed

Life sciences are innovative at their core, which means intellectual property (IP) risk management is a foundational practice. Founders operate best when they adopt defensive and offensive strategies to protect their patent moat.

The same can be said of lead scientists or founders—these key team members become an IP and operational liability the moment they leave the company. This is one of Phase I’s biggest challenges and a risk management essential, especially as founders consult and involve life sciences industry peers in the R&D of a product. Teams should ask themselves:

• What is the contractual process to involve new members in R&D?
• What are the company’s confidentiality guidelines, and how are they enforced?
• How robust is your IP risk management strategy, including response plans and insurance?

The Life Sciences Sector’s Primary Vulnerabilities

Even before Phase I and clinical trials begin, the most competitive businesses are already thinking of ways to align Good Clinical Practice (GCP) and Good Laboratory Practice (GLP). They anticipate the risks of outsourcing to Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) to create an exceptional product by mitigating risks during Phase II.

But clinical trials and FDA approval, which can cost up to $19 million, aren’t just about finding the right facilities, supply chain partners, and researching the right components. The human element is arguably one of the trickiest parts of the process, blurring the ethical and legal lines of informed consent.

This is closely followed by the risks associated with international clinical trials, like abiding by local policies and securing good standing certificates. These are just some of the myriad aspects to consider when it comes to risk management in clinical trial liability. Make sure to have clear answers to these questions:

• Are founders confident about outsourcing separate CROs and CMOs, rather than directly partnering with Contract Development and Manufacturing Organizations (CDMOs)?
• Is patient safety a priority, and are healthy patients fully aware of informed consent?
• Is the life sciences organization partnering with legal experts in the jurisdictions where trials are conducted?

When raising capital at this stage (Series A and B), it’s also critical to count on directors & officers (D&O) insurance to protect both existing founders and incoming board members. D&O coverage levels should also be sufficient to build trust with new investment partners.

The Scaling Era: Phase II, Regulatory Submission, and Managing Risk

Reaching Phase III for clinical trials on individuals with diseases is a massive milestone—in 2024, 477,220 companies registered for clinical studies, hitting a record high in the US. But that’s just the tip of the iceberg, and many companies never make it out of the R&D phase. Scaling is significant at this phase, and companies can quickly grow from hundreds to thousands of patients.

Risk management must evolve alongside operations. . For instance, supply chain disruptions will take a much bigger financial toll at this stage.

Let’s suppose an API supplier has an accident that compromises lab facilities. Can the company continue operations despite this massive setback? Is their supply chain dependent on a single solution? Contingent Business Interruption (CBI) is crucial to help life science companies roll with the punches.

Dependence on CDMOs adds further complexity—founders must forecast these major operational problems to secure funding and meet their proposed phase deadlines.

Professional liability or errors and omissions (E&O) insurance helps mitigate the risks associated with CRO oversight and data integrity during the New Drug Application (NDA), or a Biologics License Application (BLA) submission process to the FDA. This helps founders balance risk with their commitments.

When Life Sciences Organizations Pre-Launch: Preparing for Commercialization

Getting a product approved can feel impossible. But time moves fast before trials, submission, and the moment founders receive the good news. Before you know it, it’s time to gear up for commercialization. Keep in mind that growth brings new risk, and risk management strategies should evolve accordingly.

Meeting Industry Growth with Risk Mitigation Strategies

It’s easy to hit the insurance “valley of death” by forgetting to raise insurance coverage limits. Teams should review and negotiate these limits to ensure they’re appropriate for this new level of risk before the first bottle hits the shelf. Otherwise, exposure will bring greater risk to the companies’ own pocket.

Commercialization is also the moment a company starts to receive M&A offers and get IPO speculation. While this is incredibly exciting for a startup, founders must hold their horses before jumping into negotiations headfirst without first evaluating coverage. A common mistake is making massive changes at the executive level without transitioning D&O insurance coverage from private to public or M&A-ready policies.

Once the product is out in the open and ready to start improving lives, startups should shift their focus from protecting proprietary research, which may now be easily accessible to the public, to protecting trade secrets and sensitive patient data for GDPR and HIPAA purposes. This is done through, among other solutions, an evolved cyber liability insurance policy.

Market Access & Beyond: Post-Approval & Commercialization

Once a life science company has hit its commercialization phase and the product is available to those who need it, the company has made it. But that doesn’t mean that risk disappears—in fact, post-approval and commercialization represent one of the most significant periods of risk in the life science lifecycle.

Product Liability as a Key Risk Indicator

This is the main event of its risk profile—now, companies must manage the threat of mass torts, class actions, and “failure to warn” litigation (such as the cult McDonald’s hot coffee case that still makes headlines). Product liability represents crossing the finish line—the company must now take care of its product, the people who use it, and the business itself.

Failing to comply with regulatory requirements can look like just one lost document, which leads to a product recall and tarnished reputation—reputation being one of a startup’s most fragile assets. Managing the ongoing threat of FDA and EMA enforcement, labeling disputes, and pharmacovigilance is the new normal for successful life sciences companies. Keeping up with the times and shifting risk management strategies becomes par for the course.

Companies that account for new risk vectors, such as payer mix, pricing, and reimbursement dynamics, and the Health Technology Assessment (HTA), position themselves favorably in the international market. These exposures go beyond regulation requirements and become real business risks once the product is available to the public.

Cross-Lifecycle Risks for Life Sciences Companies

Employee recruitment and turnover is another prominent risk for life sciences startups, given highly specialized skillsets of any life science company’s workforce.

While this type of risk can be easy to put on the back burner, losing the wrong people can take a significant toll on a life science company and its bottom line. A proactive risk management strategy with proper employment practices liability (EPLI) coverage is more than necessary to keep employment practices in check.

Protecting Top Risks: The Physical Product

Equally, founders must start devising a protection plan for their physical product from the moment it starts manufacturing until it gets to pharmacies—refrigeration failures, theft, and transit damage are just some of the dangers life science products face.

Life science risk management is a constantly evolving process. It starts with identifying and assessing risk depth and likelihood, and continues into mitigating, monitoring, and reporting these risks. The same can be said for the product journey, which improves with time as tech and use cases help it advance. Both aspects of a life science risk management strategy must evolve together.

Building a Resilient Future in the Life Sciences Industry

Far from being a box-ticking exercise, effective risk management in life sciences brings a competitive advantage, enabling innovation and crucial partnerships that help a company’s industry share expand. The best approach is to prioritize risks and stay on top of them, in the same way core teams update a pharma product to bring it up to modern standards.

To build the best risk management strategy, startups should work with specialized insurance teams that understand industry best practices, can foresee issues unique to the life science industry, and truly understand the risks they are working to mitigate. Hiring generalist brokers often means a risk management strategy that isn’t specific or robust enough to combat real life science industry threats, leaving vital risk gaps uncovered, which often don’t come to light until it’s too late.

Today’s successful life sciences businesses ingrain risk management into their R&D DNA, enabling them to  ride the waves of economic uncertainty, geopolitical issues, and supply chain disruptions that can cripple life sciences companies and prevent potentially life-saving products from ever reaching the shelves.

Insurance Rebuilt, End-to-End

We've supported startups from stealth mode to huge funding rounds.

Get a Custom Quote